Table 2:
Variables Associated (P < 0.1) with Biochemical (A), Endoscopic (B), and Histologic (C) Remission
| Univariable analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|
| Variables | OR | 95%CI | P | OR | 95%CI | P | |
| A. Biochemical remission | |||||||
| Infliximab dosing other than 5mg/Kg every 8 weeks at time of TDM | 0.3 | 0.1–0.8 | 0.020 | 0.3 | 0.1–0.8 | 0.021 | |
| Concomitant IMM | — | — | 0.098 | 0.3 | 0.1–0.9 | 0.040 | |
| Infliximab TC ≥2.2 μg/mL | 5.9 | 1.5–22.3 | 0.014 | 6.4 | 1.5–27.1 | 0.011 | |
| B. Endoscopic remission | |||||||
| Concomitant IMM | — | — | 0.065 | — | — | — | |
| Infliximab TC ≥ 9.7 μg/mL | 3.6 | 1.4–9 | 0.006 | 3.6 | 1.4–9 | 0.006 | |
| B. Histologic remission | |||||||
| Male | 0.4 | 0.2–0.9 | 0.032 | 0.4 | 0.2–0.9 | 0.035 | |
| Infliximab TC ≥ 9.8 μg/mL | 3.3 | 1.4–7.9 | 0.010 | 3.2 | 1.3–7.9 | 0.011 | |